Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness
McNamee P, Parkin D
Record ID 31999009899
English
Authors' objectives:
This paper describes and updates a previous study which was funded by the NHS HTA programme to investigate the cost-effectiveness of interferon beta-1b for the treatment of RRMS. Since publication of the 1998 report, important new evidence has become available on the effectiveness of interferon beta and, additionally, in secondary progressive disease.
Authors' recommendations:
The values provided in this updated report are substantially higher than those calculated in the previous report (328,300 and 228,300 GBP per QALY gained for 5 and 10 years respectively). It can be inferred therefore that the validity of the previous conclusions, which stated that therapy produces small short-term gains for large additional costs, are further strengthened as a result of incorporating new trial evidence.
Authors' methods:
Cost study
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/987
Year Published:
1998
URL for published report:
http://www.hta.ac.uk/971
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Costs and Cost Analysis
- Interferon-beta
- Multiple Sclerosis
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.